November 19, 2026

  UPFRONT BRIEFING

Pfizer is putting $330M upfront on Starna's in vivo CAR-T, three pre-IND autoimmune programs plus the platform, for a headline of up to $2.6B. It is Pfizer's first step into building CAR-T cells inside the body, and another China licence for a company that treats China as a second BD office. Over at CTAD, Bristol Myers finally showed some ADEPT data for Cobenfy in Alzheimer's psychosis, though open-label numbers are a trailer, not the film.

Regeneron also picked up its first neurology approval, a myasthenia gravis siRNA dosed four times a year. Jefferies London wraps today and CTAD runs on in Boston; Capricor's deramiocel PDUFA lands Sunday.

TAPE ACTION

  • Healthcare was the second-worst S&P sector, XLV (2.2%), as managed care extended its slide on the proposed CMS Medicare Advantage audit-extrapolation (CRUSH) rule, first floated Monday night: Humana (13.0%), UnitedHealth (10.2%), Elevance (7.6%), Centene (7.0%), CVS (5.2%). Biotech lost less: XBI (0.2%), NBI (0.7%), BBC (1.0%).

  • The S&P 500 fell 0.2% for a fifth straight loss and the Dow lost 561 points (1.1%) on UnitedHealth, while the Nasdaq 100 rose 0.4% even as Nvidia (2.9%) reversed early gains after its board said Jensen Huang will not return as CEO. FOMC minutes showed almost all officials saw further hikes as likely appropriate (Kalshi: 91% for a December hike); the 10-year fell 3bp to 5.07%, WTI dropped 3.2% to $83.26 and energy was the worst sector. After the bell, Anthropic priced its IPO at $83, above the $70-78 range; it trades today.

THE BIG 3

1️⃣ — Pfizer licenses Starna's in vivo CAR-T for $330M upfront, up to $2.6B

  • Pfizer licensed ex-Greater China rights to three pre-IND in vivo CAR-T programs for autoimmune disease from China's Starna Therapeutics: $330M upfront, up to $2.3B in development and commercial milestones, plus royalties. Pfizer also gets Starna's targeted-LNP CAR-T technology for I&I and oncology, options on research-collaboration compounds and on Greater China, and will make clinical supply in the US.

  • Why it matters: Pfizer is paying $330M in cash for three programs with no human data, about 13% of the $2.6B headline at signing. The platform rights are the real purchase: AstraZeneca, AbbVie, Gilead and BMS have each bought in vivo CAR-T companies and Lilly has done two buyouts this year, so an unclaimed delivery platform is getting scarce. Starna's pitch is RNA in targeted LNPs, which plays to Pfizer's Comirnaty manufacturing base. It is at least Pfizer's fifth major China alliance since early 2025, after the $10.5B Innovent pact. Two overhangs: COINS Act scrutiny of China-sourced licensing, and the Novartis and BMS autoimmune CAR-T trial pauses after safety events, including deaths.

  • Source: Endpoints

2️⃣ — BMS opens the ADEPT books: open-label Cobenfy data in Alzheimer's psychosis

  • Bristol Myers presented the first ADEPT data at CTAD in Boston. In ADEPT-1's 12-week open-label lead-in (273 of 320 completed), KarXT cut NPI-C hallucinations and delusions by 12.0 points from a 14.4 baseline; TEAEs 56.6%, serious 5.0%, discontinuations 4.4%. In the ADEPT-3 52-week extension (273 of 401 completed), TEAEs were 65.1%, serious 7.7%, discontinuations 4.7%. All double-blind data remain blinded.

  • Why it matters: These are descriptive numbers from patients who finished an open-label period, so they show feasibility, not efficacy. ADEPT-1's primary endpoint, time to relapse in a 26-week randomized withdrawal, stays blinded until 2027. Tolerability is the read analysts wanted: adverse events in 56.6% of elderly patients over 12 weeks, though discontinuations held under 5%. That matters for a drug BMS bought with Karuna for $14B and whose schizophrenia launch has been slowed by side effects. Truist models $2.6B in worldwide Cobenfy sales and called the update incremental. ADEPT has already been delayed at least twice, once over site irregularities, so the 2027 placebo-controlled data carry the expansion case.

  • Source: BioSpace

3️⃣ — Regeneron's Livsayis wins FDA nod as a four-times-a-year myasthenia drug

  • FDA approved Regeneron's Livsayis (cemdisiran), a C5-directed siRNA, for AChR antibody-positive adults with generalized myasthenia gravis, given subcutaneously four times a year. In Phase 3 NIMBLE, MG-ADL improved 4.5 points vs 2.2 on placebo at week 24 (placebo-adjusted 2.3, p=0.0005) and QMG 4.2 vs 1.5 (p=0.0015).

  • Why it matters: NIMBLE's effect is solid rather than spectacular: 76.6% of patients hit a 3-point MG-ADL response versus 44.1% on placebo, and 48.4% a 5-point QMG response versus 19.0%. The selling point is the schedule, one subcutaneous shot a quarter, against Ultomiris infusions every eight weeks and AstraZeneca's once-weekly self-injected Klygefa, approved Monday. That gives Regeneron a convenience pitch into the C5 market Alexion built, alongside argenx's FcRn franchise. It is Regeneron's first siRNA and first neurology approval, arriving as US Eylea fell 41% in Q3. The label covers only AChR antibody-positive adults, and C5 blockade carries a class meningococcal-infection risk.

EVERYTHING ELSE THAT BROKE

  • FDA approved Sanofi's Infilbray (venglustat), an oral brain-penetrant glucosylceramide synthase inhibitor, for neurological manifestations of Type 3 Gaucher disease; Phase 3 LEAP2MONO beat imiglucerase on a global test of neurological endpoints (p=0.0137). — Sanofi release

  • nChroma halted its only clinical study early and cut 50% of staff in a sharp reset. — Endpoints

  • Teva R&D chief and CMO Eric Hughes is leaving for an outside role; David Gardiner leads R&D while Teva searches for a successor. — Teva release

  • FDA moved to withdraw approval of Salerno's liquid cholesterol drug over missing required reports. — Fierce Pharma

DEAL FLOW

Track the Deals Shaping Biotech

Track M&A, licensing agreements, IPOs and venture financings. Explore deal values, key terms and transaction details in our regularly updated BioBucks trackers.

M&A / BD&L

  • Pfizer / Starna Therapeutics: ex-Greater China licence to three pre-IND in vivo CAR-T autoimmune programs plus platform rights in I&I and oncology; $330M upfront, up to $2.3B milestones, royalties (see The Big 3). — Pfizer release

  • Vertex / Genomics: discovery collaboration extended by four years (eight already behind it), worth up to $220M (Tue 17 Nov). — Fierce Biotech

VC / PRIVATE FINANCINGS

  • VitriVax raised an oversubscribed $87M Series C, co-led by F-Prime, NEA, RA Capital and Sanofi Ventures with Eli Lilly joining, to take its thermostable Lyme disease vaccine into first-in-human testing. — VitriVax release

  • Commit Biologics (Denmark) closed a $60M seed led by Ackermans & van Haaren, joined by AbbVie Ventures and M Ventures, with Novo Holdings, Bioqube and Korys returning; complement-engaging COM002 for R/R NHL targets first dosing early 2028 (announced Tue). — BioPharm International

IPO / FOLLOW-ON

  • Sellas Life Sciences (SLS) priced its $150M follow-on: 11,538,462 shares at $13.00 (+1,730,769 option), J.P. Morgan and TD Cowen leading, close 20 Nov; galinpepimut-S REGAL Phase 3 AML data ran in yesterday's Big 3. — Sellas release

ACADEMIC CORNER

  • NEJM reviewed acute respiratory distress syndrome, covering management from underlying-cause treatment to prone positioning and ECMO. — NEJM

  • NEJM examined the expanding evidence and indications for thrombectomy in ischemic stroke. — NEJM

  • Cell highlighted DAQplugin, a ChimeraX tool for deep-learning validation of cryo-EM protein models. — Cell

Know someone who'd like this?

Forward it along. It takes ten seconds and means a lot to us.

Pfizer is paying to make T cells inside the body. We are still working on making coffee inside the office.

— The BioBucks Team